2013
High Frequency of Putative Ovarian Cancer Stem Cells With CD44/CK19 Coexpression Is Associated With Decreased Progression-Free Intervals In Patients With Recurrent Epithelial Ovarian Cancer
Liu M, Mor G, Cheng H, Xiang X, Hui P, Rutherford T, Yin G, Rimm DL, Holmberg J, Alvero A, Silasi DA. High Frequency of Putative Ovarian Cancer Stem Cells With CD44/CK19 Coexpression Is Associated With Decreased Progression-Free Intervals In Patients With Recurrent Epithelial Ovarian Cancer. Reproductive Sciences 2013, 20: 605-615. PMID: 23171677, PMCID: PMC3635069, DOI: 10.1177/1933719112461183.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnalysis of VarianceBiomarkers, TumorCarcinoma, Ovarian EpithelialDisease ProgressionDisease-Free SurvivalDrug Resistance, NeoplasmFemaleHumansHyaluronan ReceptorsKaplan-Meier EstimateKeratin-19Middle AgedMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasm StagingNeoplasms, Glandular and EpithelialNeoplastic Stem CellsOvarian NeoplasmsProportional Hazards ModelsRetrospective StudiesRisk FactorsTime FactorsTreatment OutcomeConceptsPutative ovarian cancer stem cellsOvarian cancer stem cellsProgression-free intervalCancer stem cellsRecurrent epithelial ovarian cancerShorter disease-free intervalShorter progression-free intervalDisease-free intervalResidual tumor volumeEpithelial ovarian cancerLog-rank testEpithelial ovarian cancer cellsIndependent significant predictorsAdvanced stage EOCOvarian cancer cellsStem cellsMean followObstetrics stageUnivariable analysisClinicopathologic featuresMultivariable analysisRetrospective studyPrognostic valueOvarian cancerTumor volume
2010
In Situ Identification of Putative Cancer Stem Cells by Multiplexing ALDH1, CD44, and Cytokeratin Identifies Breast Cancer Patients with Poor Prognosis
Neumeister V, Agarwal S, Bordeaux J, Camp RL, Rimm DL. In Situ Identification of Putative Cancer Stem Cells by Multiplexing ALDH1, CD44, and Cytokeratin Identifies Breast Cancer Patients with Poor Prognosis. American Journal Of Pathology 2010, 176: 2131-2138. PMID: 20228222, PMCID: PMC2861079, DOI: 10.2353/ajpath.2010.090712.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAldehyde DehydrogenaseAldehyde Dehydrogenase 1 FamilyBreast NeoplasmsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansHyaluronan ReceptorsIsoenzymesKeratinsMiddle AgedNeoplastic Stem CellsPrognosisRetinal DehydrogenaseRetrospective StudiesConceptsCancer stem cellsPutative cancer stem cellsBreast cancerIdentifies high-risk patientsPresence of CSCsNode-positive patientsHigh-risk patientsBreast cancer patientsAggressive tumor behaviorParaffin-embedded breast cancer tissuesBreast cancer tissuesFlow cytometric studyStem cellsMean followNodal statusRisk patientsTumor persistenceCD44 positivityPoor prognosisPrognostic valueTumor sizeHistological gradeALDH1 positivityCancer patientsWorse outcomes
2006
Evaluation of the Prognostic Value of Cellular Inhibitor of Apoptosis Protein in Epithelial Ovarian Cancer Using Automated Quantitative Protein Analysis
Psyrri A, Yu Z, Bamias A, Weinberger PM, Markakis S, Kowalski D, Camp RL, Rimm DL, Dimopoulos MA. Evaluation of the Prognostic Value of Cellular Inhibitor of Apoptosis Protein in Epithelial Ovarian Cancer Using Automated Quantitative Protein Analysis. Cancer Epidemiology Biomarkers & Prevention 2006, 15: 1179-1183. PMID: 16775178, DOI: 10.1158/1055-9965.epi-06-0120.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerOvarian cancerPrognostic valuePaclitaxel-based combination chemotherapyOnly significant prognostic factorAdvanced stage ovarian cancerSignificant prognostic factorsOvarian cancer patientsProtein levelsImportant prognostic biomarkerMean followSurgical debulkingCombination chemotherapyOverall survivalPrognostic factorsClinical outcomesMultivariable analysisEntire cohortCancer patientsPrognostic biomarkerPrognostic variablesMembranous expressionApoptosis proteinSurvival rateCellular inhibitor
2005
Subcellular Localization and Protein Levels of Cyclin-Dependent Kinase Inhibitor p27 Independently Predict for Survival in Epithelial Ovarian Cancer
Psyrri A, Bamias A, Yu Z, Weinberger PM, Kassar M, Markakis S, Kowalski D, Efstathiou E, Camp RL, Rimm DL, Dimopoulos MA. Subcellular Localization and Protein Levels of Cyclin-Dependent Kinase Inhibitor p27 Independently Predict for Survival in Epithelial Ovarian Cancer. Clinical Cancer Research 2005, 11: 8384-8390. PMID: 16322299, DOI: 10.1158/1078-0432.ccr-05-1270.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCell DifferentiationCohort StudiesCombined Modality TherapyCyclin-Dependent Kinase Inhibitor p27Cystadenocarcinoma, SerousFemaleHumansMiddle AgedNeoplasm StagingNeoplasms, Glandular and EpithelialOvarian NeoplasmsPrognosisSubcellular FractionsSurvival RateTissue Array AnalysisConceptsNuclear p27 expressionOvarian cancerP27 expression levelsOverall survivalP27 expressionPlatinum-paclitaxel combination chemotherapyAdvanced stage ovarian cancerDisease-free survivalSignificant prognostic factorsStage ovarian cancerEpithelial ovarian cancerValuable prognostic biomarkerExpression levelsP27 protein expressionCyclin-dependent kinase inhibitor p27Mean followSurgical debulkingCombination chemotherapyPrognostic factorsMultivariable analysisPrognostic valueImmunohistochemical assessmentPrognostic biomarkerPrognostic variablesImmunofluorescence-based methodβ-Catenin Functions Mainly as an Adhesion Molecule in Patients with Squamous Cell Cancer of the Head and Neck
Yu Z, Weinberger PM, Provost E, Haffty BG, Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A. β-Catenin Functions Mainly as an Adhesion Molecule in Patients with Squamous Cell Cancer of the Head and Neck. Clinical Cancer Research 2005, 11: 2471-2477. PMID: 15814622, DOI: 10.1158/1078-0432.ccr-04-2199.Peer-Reviewed Original ResearchConceptsSquamous cell cancerCyclin D1 levelsCell cancerNeck squamous cell cancerAdhesion moleculesD1 levelsDisease-free survivalIndependent prognostic factorLocal recurrence rateKaplan-Meier analysisMembranous expression patternLow cyclin D1Cancer tissue microarrayIncidence of mutationsProtein expression levelsMean followHazard ratioPrognostic factorsLocal recurrencePathologic dataCox regressionRecurrence rateMetastasis stageTissue microarrayBeta-catenin expressionCyclin D1 Is a Valuable Prognostic Marker in Oropharyngeal Squamous Cell Carcinoma
Yu Z, Weinberger PM, Haffty BG, Sasaki C, Zerillo C, Joe J, Kowalski D, Dziura J, Camp RL, Rimm DL, Psyrri A. Cyclin D1 Is a Valuable Prognostic Marker in Oropharyngeal Squamous Cell Carcinoma. Clinical Cancer Research 2005, 11: 1160-1166. PMID: 15709184, DOI: 10.1158/1078-0432.1160.11.3.Peer-Reviewed Original ResearchConceptsOropharyngeal squamous cell carcinomaDisease-free survivalSquamous cell carcinomaCyclin D1Overall survivalCell carcinomaPrognostic markerOropharyngeal squamous cell cancerProtein expressionLocal recurrence rateMultivariate Cox regressionLong-term followSquamous cell cancerCyclin D1 expression levelsNuclear cyclin D1 expressionTerms of prognosisCell cycle regulator cyclin D1Valuable prognostic markerExpression levelsCyclin D1 expressionProtein expression levelsMean followIndependent predictorsLocal recurrenceCell cancer
2003
Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival.
Berger AJ, Kluger HM, Li N, Kielhorn E, Halaban R, Ronai Z, Rimm DL. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Research 2003, 63: 8103-7. PMID: 14678960.Peer-Reviewed Original ResearchConceptsATF2 expressionTranscription factor 2Melanoma specimensUseful prognostic markerEarly-stage melanomaWeak cytoplasmic stainingStrong nuclear stainingFactor 2Mean followCutaneous specimensLocalized diseaseOverall survivalIndependent predictorsPreclinical findingsClark levelClinicopathological dataPatient survivalPoor outcomePrognostic valueWorse outcomesPrognostic markerPoor survivalPreclinical modelsClinical significanceImmunohistochemical staining